NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03/03/2026
Back to search
Official data from USPTO
DOSE-2-WEIGHT SYRINGE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DOSE-2-WEIGHT SYRINGE
ST13
US500000086414662Class
5
Filing
86414662
Registration
4871749
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
03/24/2026
Trademark type
Word
Nice classes
5
Filing date
10/03/2014
Registration date
12/15/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/03/2026
Last transaction
03/24/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2015-08-00
First use in commerce
2015-08-00
Drawing code
4
Owner type
16
Owner location
Bradenton, FL, US
Examiner
DUBRAY, KATHERINE M
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Asepsis Medical Technologies, LLC
Asepsis Medical Technologies, LLC
Representatives
Asepsis Medical Technologies, LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; Antiemetics; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of inflammatory disordersfor use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical products for ophthalmological use; Potassium preparations for pharmaceutical purposes; Vitamin and mineral preparations for medical use
Publications
History of USPTO decisions and trademark events.
39 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
03/03/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03/03/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/03/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
12/08/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
12/15/2024
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
08/31/2022
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
08/31/2022
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
08/30/2022
PUM1
OFFICE ACTION ISSUED POU1
03/29/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/15/2022
ES8R
TEAS SECTION 8 RECEIVED
03/01/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/15/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/15/2015
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/13/2015
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/12/2015
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/20/2015
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/20/2015
IUAF
USE AMENDMENT FILED
10/08/2015
EISU
TEAS STATEMENT OF USE RECEIVED
10/08/2015
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/22/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/28/2015
PUBO
PUBLISHED FOR OPPOSITION
07/28/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/08/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/25/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/24/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/16/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/16/2015
ALIE
ASSIGNED TO LIE
06/08/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/29/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/28/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/28/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/29/2015
GNRT
NON-FINAL ACTION E-MAILED
01/29/2015
CNRT
NON-FINAL ACTION WRITTEN
01/29/2015
DOCK
ASSIGNED TO EXAMINER
01/22/2015
MPMK
NOTICE OF PSEUDO MARK E-MAILED
10/11/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/10/2014
NWAP
NEW APPLICATION ENTERED
10/07/2014
Continuous trademark protection
Get notified about every new filing that threatens DOSE-2-WEIGHT SYRINGE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.